Clinical Trial Update: Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing once-daily 150 mg itopride to thrice-daily 50 mg in functional dyspepsia has completed. Results have been posted (2026-04-03).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Functional Dyspepsia

Drugs mentioned

• itopride (itopride)

Snippet

Sponsor: Abbott | Conditions: Functional Dyspepsia | Phase 3 | Status: COMPLETED | Results posted: 2026-04-03